Výsledky vyhledávání - "Venkata Kumari Bachanaboyina"

Supplementary information from Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias

Autor: Jukka Westermarck, Maija Itälä-Remes, Claire M. Lucas, Venkata Kumari Bachanaboyina, Laura L. Elo, Richard E. Clark, Veli-Matti Kähäri, Tea Ammunét, Srikar G. Nagelli, Eliisa Löyttyniemi, Urpu Salmenniemi, Taru Varila, Karolina Pavic, Eleonora Mäkelä

Supplementary tables S1-S5 and supplementary figures S1-S5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::719326290e46c0e1fbf0e57e719f057d
https://doi.org/10.1158/1078-0432.22479393.v1

Zobrazit plný text záznamu

Data from Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias

Purpose:Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56α. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2A splicing variant, novel CIP2A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fafacee52720caa917ca11aea05890f
https://doi.org/10.1158/1078-0432.c.6530211

Zobrazit plný text záznamu

Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias

Autor: Karolina Pavic, Taru Varila, Eliisa Löyttyniemi, Claire M. Lucas, Jukka Westermarck, Eleonora Makela, Maija Itälä-Remes, Tea Ammunét, Veli-Matti Kähäri, Richard E. Clark, Venkata Kumari Bachanaboyina, Urpu Salmenniemi, Laura L. Elo, Srikar G. Nagelli

Publikováno v: CLINICAL CANCER RESEARCH

Purpose: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56α. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2A splicing variant, novel CIP2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f01de7f040e479f4bb3dda9a2eb81b8
https://doi.org/10.1158/1078-0432.ccr-20-3679

Zobrazit plný text záznamu

Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias

Autor: Karolina Pavic, Eliisa Löyttyniemi, Maija Itälä-Remes, Venkata Kumari Bachanaboyina, Claire M. Lucas, Veli-Matti Kähäri, Urpu Salmenniemi, Taru Varila, Richard E. Clark, Jukka Westermarck, Srikar G. Nagelli, Eleonora Makela

Cancerous inhibitor of PP2A (CIP2A) is a prevalent human oncoprotein that inhibits tumor suppressor PP2A-B56a. However, CIP2A mRNA and protein variants remain uncharacterized. Here, we report discovery of a CIP2A splicing variant NOCIVA (NOvel CIp2a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80f4733f0e800e332c27ee179d8fc011
https://doi.org/10.1101/2020.08.24.264606

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání